Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Genome editing treats muscular dystrophy in mice

11 January 2016

By Jenny Sharpe

Appeared in BioNews 834

Scientists in the USA have shown that the genome-editing technology CRISPR can improve muscle function in a mouse model of Duchenne muscular dystrophy (DMD).

This marks the first time that CRISPR has been successfully used to improve the symptoms of a fully developed mammal with a genetic disease. The studies were carried out by three independent research groups and were published side by side in Science.

'This is different from other therapeutic approaches because it eliminates the cause of the disease,' said Dr Eric Olson, who led one of the groups at the University of Texas Southwestern Medical Center.

DMD is a progressive muscle-wasting disease caused by mutations in the dystrophin gene. This leads to a deficiency of dystrophin protein, which is important in supporting the muscle fibres during contraction; without dystrophin, the muscle fibres become damaged and stop working.

As the DMD mouse model has a mutation in exon 23 of the dystrophin gene, the scientists designed a CRISPR system that would effectively delete this exon and result in a shorter but functional version of the dystrophin protein.

They packaged the system into a harmless virus called an adeno-associated virus, which was then injected into the DMD mice. This resulted in increased dystrophin expression in the heart and muscle of injected mice. Although the injected mice were significantly stronger than the non-injected mice, they were still weaker than healthy wild-type mice.

The ethical implications of CRISPR technology have been under much debate since Chinese scientists used it to genetically modify human embryos (see BioNews 799).

Dr Charles Gersbach, who led the research group at Duke University in North Carolina, said: 'Recent discussion about CRISPR to correct genetic mutations in human embryos has rightfully generated considerable concern regarding the ethical implications of such an approach. But using CRISPR to correct genetic mutations in the affected tissues of sick patients is not under debate.'

He added: 'These studies show a path where that is possible, but there is still a considerable amount of work to do.'

There is currently no effective treatment for DMD, which reduces life expectancy to about 30 years.

Robert Meadowcroft, Chief Executive of Muscular Dystrophy UK, said: 'It is vital that research using CRISPR technology continues to move forward. This kind of early-stage innovative research could being the next generation of therapies onto the horizon.'

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

09 October 2017 - by Emma Laycock 
Scientists have repaired the faulty gene in a mouse model of muscular dystrophy by using gold nanoparticles to deliver the genome editing tool CRISPR-Cas9...
31 July 2017 - by Jenny Sharpe 
A safe and effective gene therapy treating Duchenne muscular dystrophy in dogs has been demonstrated...
27 March 2017 - by Emma Laycock 
Radiolab explores the science, the uses and the ethics of CRISPR in this podcast that was two years in the making...
13 February 2017 - by Caroline Casey 
Scientists have identified a unique form of congenital muscular dystrophy, characterised by short stature, intellectual disabilities and cataracts...
01 February 2016 - by Kulraj Singh Bhangra 
Researchers have used the CRISPR/Cas9 genome-editing technique to correct a genetic mutation that causes blindness...

16 November 2015 - by Jenny Sharpe 
Researchers have discovered a gene linked to Duchenne muscular dystrophy (DMD) after a dog bred to model the disease was found to have a protective mutation against it...
26 October 2015 - by Isobel Steer 
Scientists in China have used the gene-editing technique CRISPR/Cas9 to create dogs with increased muscle mass...
23 September 2013 - by Dr Anna Cauldwell 
A highly anticipated experimental treatment for the genetic condition Duchenne Muscular Dystrophy has failed in a key test of its effectiveness in a critical phase III clinical trial.
01 August 2011 - by Dr Nadeem Shaikh 
UK researchers have successfully trialled a new drug to help patients with a severe form of muscular dystrophy....
13 June 2011 - by Sarah Pritchard 
The NHS must be prepared to screen every newborn baby for Duchenne muscular dystrophy (DMD) – the most severe form of muscular dystrophy – in three years time, says a leading UK geneticist who explains that promising treatments are close to becoming a reality...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation